Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Radiation Dosimetry, Pharmacokinetics, and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 Injection in Patients With Prostate Cancer

NCT07765940 is registered in ClinicalTrials.gov with RadAlliance Therapeutics, Inc as lead sponsor.

NCT NCT07765940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07765940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Radiation Dosimetry, Pharmacokinetics, and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 Injection in Patients With Prostate Cancer
Lead sponsor
RadAlliance Therapeutics, Inc
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 15, 2026
Completion date
December 31, 2027
Enrollment
52 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer